Investment Thesis
Inspire Medical Systems (NYSE: INSP) is the dominant player in hypoglossal nerve stimulation (HGNS) for obstructive sleep apnea (OSA), offering a minimally invasive alternative to CPAP. With a durable competitive moat from its proprietary technology and over 1,000 trained implant centers, Inspire is poised to capture a growing share of the 30 million OSA patients in the US alone. The company is transitioning from a high-growth, cash-burning phase to a self-sustaining, profitable growth story, with revenue growth of 25%+ and expanding operating margins.
12-Month Catalysts
- Procedure Volume Acceleration: Inspire has guided for 30%+ procedure growth in 2026, driven by increased patient awareness and surgeon training. Q1 2026 results showed 35% year-over-year procedure growth, beating expectations.
- FDA Label Expansion: The company is pursuing FDA approval for a pediatric indication and a simplified implant procedure, which could expand the addressable market by 20-30%.
- International Expansion: Inspire is ramping up in Europe and Asia, with Japan and Germany as key markets. International revenue grew 50% in 2025 and is expected to accelerate.
- CMS Coverage Expansion: Potential expansion of Medicare coverage to include milder OSA patients (AHI 5-15) could double the eligible patient population.
- Margin Inflection: Gross margins are expanding as manufacturing scales, and operating leverage is driving EBITDA positivity by late 2026.
Key Risks
- Competition from Rival Devices: LivaNova’s aura6000 and Nyxoah’s Genio system are potential competitors, though Inspire’s first-mover advantage and clinical data provide a buffer.
- Reimbursement Risk: Any changes to CMS coverage or private payer policies could slow procedure growth. However, current trends are favorable.
Valuation Summary
At ~$180 per share, INSP trades at 7.5x 2026E sales and 35x 2026E EBITDA. This is a premium to medtech peers, but justified by 25%+ revenue growth and a path to 20%+ EBITDA margins by 2028. Our price target of $235 implies 30% upside, based on 9x 2027E sales.
Balance Sheet Summary
Inspire has $450 million in cash and no debt, providing ample runway to fund growth and potential M&A. Operating cash flow turned positive in Q4 2025, and we expect free cash flow positivity by H2 2026.
Disclaimer: This is not financial advice. All investments carry risk. Please conduct your own due diligence or consult a financial advisor before making investment decisions.